
Lytix Biopharma (Q3 Review) - Positive Clinical Readouts

Redeye comments on Lytix' third quarter report 2025. After the quarter, positive results were presented in both main programmes. Lytix presented a strong interim readout in NeoLIPA, the study in neoadjuvant melanoma, while Verrica disclosed immune activation in biopsies of BCC.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Lytix Biopharma (Q3 Review) - Positive Clinical Readouts